U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT06973681) titled 'A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese Subjects' on May 14.
Brief Summary: To assess the effect of BGM0504 injection versus placebo on weight loss in overweight or obese subjects after 24 weeks of treatment.
Study Start Date: Oct. 13, 2023
Study Type: INTERVENTIONAL
Condition:
Overweight or Obesity
Intervention:
DRUG: BGM0504
Administered SC
DRUG: BGM0504
Administered SC
DRUG: BGM0504
Administered SC
DRUG: Placebo
Administered SC
Recruitment Status: COMPLETED
Sponsor: BrightGene Bio-Medical Technology Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily...